Clinical Trial Detail

NCT ID NCT01522768
Title Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

esophageal cancer

stomach cancer

Therapies

Afatinib + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST